Clinical Trials Logo

Oligodendroglioma clinical trials

View clinical trials related to Oligodendroglioma.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT05297864 Terminated - Clinical trials for Recurrent Glioblastoma

PARP Inhibition for Gliomas (PI-4G or π4g)

OU-SCC-PI-4G
Start date: June 9, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine what effects (good and bad) niraparib has on patients with recurrent brain cancer.

NCT ID: NCT03971734 Terminated - Glioblastoma Clinical Trials

Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

Start date: December 6, 2019
Phase: Phase 1
Study type: Interventional

enroll patients with histologically confirmed high-grade gliomas to evaluate the ability of regadenoson to transiently disrupt a relatively intact blood-brain barrier (BBB). determine the best dose of regadenoson to disrupt the BBB and allow for enhanced penetration of gadolinium during MRI.

NCT ID: NCT02967380 Terminated - Multiple Sclerosis Clinical Trials

Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases

Start date: December 14, 2011
Phase: N/A
Study type: Interventional

This pilot clinical trial compares gadobutrol with standard of care contrast agents, gadopentetate dimeglumine or gadobenate dimeglumine, before dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) in diagnosing patients with multiple sclerosis, grade II-IV glioma, or tumors that have spread to the brain. Gadobutrol is a type of contrast agent that may increase DCE-MRI sensitivity for the detection of tumors or other diseases of the central nervous system. It is not yet known whether gadobutrol is more effective than standard of care contrast agents before DCE-MRI in diagnosing patients with multiple sclerosis, grade II-IV glioma, or tumors that have spread to the brain.

NCT ID: NCT02924038 Terminated - Glioma Clinical Trials

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

Start date: April 3, 2017
Phase: Phase 1
Study type: Interventional

This is a pilot, randomized, two arm neoadjuvant vaccine study in human leukocyte antigen-A2 positive (HLA-A2+) adults with World Health Organization (WHO) grade II glioma, for which surgical resection of the tumor is clinically indicated. Co-primary objectives are to determine: 1) the safety of the novel combination of subcutaneously administered IMA950 peptides and poly-ICLC (Hiltonol) and i.v. administered CDX-1127 (Varlilumab) in the neoadjuvant approach; and 2) whether addition of i.v. CDX-1127 (Varlilumab) increases the response rate and magnitude of CD4+ and CD8+ T-cell responses against the IMA950 peptides in post-vaccine peripheral blood mononuclear cell (PBMC) samples obtained from participating patients.

NCT ID: NCT02764151 Terminated - Malignant Glioma Clinical Trials

First in Patient Study for PF-06840003 in Malignant Gliomas

Start date: September 9, 2016
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety and tolerability of increasing doses of PF-06840003 in patients with malignant gliomas.

NCT ID: NCT02255461 Terminated - Clinical trials for Recurrent Childhood Medulloblastoma

Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

Start date: December 8, 2014
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of palbociclib isethionate in treating younger patients with central nervous system tumors that have grown, come back, or not responded to treatment. Palbociclib isethionate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02175745 Terminated - Adult Glioblastoma Clinical Trials

18F FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly Diagnosed or Recurrent Gliomas

Start date: December 2014
Phase: N/A
Study type: Interventional

This clinical trial compares fluorine F 18 fluorodopa (18F FDOPA) positron emission tomography (PET) with standard magnetic resonance imaging (MRI) in measuring tumors in patients with glioma that is newly diagnosed or recurrent (has returned). 18F FDOPA is a radioactive drug that binds to tumor cells and is captured in images by PET. Computed tomography (CT) and MRI are used with PET to describe information regarding the function, location, and size of the tumor. PET/CT or PET/MRI may be more accurate than standard MRI in helping doctors find and measure brain tumors.

NCT ID: NCT02168270 Terminated - Glioblastoma Clinical Trials

Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma

Start date: June 16, 2014
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of ascorbic acid when given together with temozolomide in treating patients with high-grade glioma that has come back. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ascorbic acid contains ingredients that may prevent or slow the growth of high-grade gliomas. Giving temozolomide with ascorbic acid may kill more tumor cells.

NCT ID: NCT02031965 Terminated - Clinical trials for Recurrent Childhood Glioblastoma

Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery

Start date: December 2013
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and the safety of injecting HSV1716 (a new experimental therapy) into or near the tumor resection cavity. The injection will be done at the time of surgery. HSV1716 is a virus that has a gene which has been changed or removed (mutated) in such a way that lets the virus multiply in dividing cells of the tumor and kills the tumor cells.

NCT ID: NCT02023905 Terminated - Low Grade Glioma Clinical Trials

Everolimus With and Without Temozolomide in Adult Low Grade Glioma

Start date: March 19, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out what effects, good and/or bad, everolimus (RAD001, also known as Afinitor®) alone or with temozolomide has on the patient and the patient's low-grade glioma. Everolimus is being investigated as an anticancer agent based on its potential to prevent tumor cells from growing and multiplying. Specifically, there is a protein called mTOR that we think helps many tumors to grow, and everolimus blocks the effect of mTOR. Temozolomide is also an anticancer agent that prevents tumor cells from growing and multiplying.